<?xml version="1.0" encoding="UTF-8"?>
<p>After the Davos 2016 meeting, 3 task teams convened in 2016 between February and June to define sustainable solutions for development of EID vaccines to improve global preparedness and response capacity (
 <xref rid="ref6" ref-type="bibr">6</xref>, 
 <xref rid="ref11" ref-type="bibr">11â€“13</xref>). The task teams comprised 200 thought leaders and experts representing more than 80 organizations, who drew insights from WHO Blueprint priorities (
 <xref rid="ref12" ref-type="bibr">12</xref>), industry, and civil-society perspectives on the role of vaccines for the prevention of humanitarian crises caused by EIDs. Each task team explored challenges for the development of EID vaccines that could be used in epidemics, including pathogen prioritization, clinical development, manufacturing capacity, regulatory pathways, models for product development partnerships, and funding strategies (
 <xref rid="ref13" ref-type="bibr">13</xref>, 
 <xref rid="ref14" ref-type="bibr">14</xref>).
</p>
